Merck (MRK) Announces LYNPARZA Demonstrated OS Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. AWK
8. DRI
9. ULS
10. PRME

Go back to Merck (MRK) Announces LYNPARZA Demonstrated OS Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Merck & Co. (NYSE: MRK) Delayed: 148.78 +0.80 (0.54%)
Previous Close $147.98    52 Week High $65.46 
Open $148.06    52 Week Low $47.97 
Day High $149.98    P/E 101.21 
Day Low $147.48    EPS $1.47 
Volume 8,290,254